Diabetes Magna Plus™
Magnetic Precision. Metabolic Remission.
Minimally invasive magnetic duodeno-ileal anastomosis for rapid Type 2 diabetes remission and metabolic reset. No permanent implants.
What is Diabetes Magna Plus™?
A minimally invasive procedure creating a targeted intestinal bipartition using magnetic compression. No permanent implants — magnets pass naturally after healing. Triggers powerful gut hormone changes for glycemic control.
Who it's for: Type 2 Diabetes patients seeking a focused, effective solution — with or without major obesity.
- Magnetic Precision for safe, reliable healing
- Rapid metabolic remission
- Lower malnutrition risk vs traditional bypass
- Faster recovery — ideal for medical tourism
- Backed by FDA-cleared magnetic anastomosis technology
A clear, precise pathway.
- 01
Magnet placement
Two small magnets are delivered laparoscopically/endoscopically.
- 02
Auto-alignment & compression
The magnets self-align and gently compress tissue.
- 03
Natural anastomosis forms
Over days, a stable side-to-side duodeno-ileal connection forms.
- 04
Magnets expel naturally
Implants pass naturally — metabolic remission begins.
Ready for Magnetic Precision. Metabolic Remission?
Speak with our international care team today — same-week availability.
The science behind Diabetes Magna Plus™.
Amplify your results with science-backed protocols.
Pair Diabetes Magna Plus™ with personalized pre- and post-op bundles from MyProgressMD — engineered to support healing, nutrition, and long-term metabolic outcomes.
Shop Supplement BundlesCurrent Evidence Status
A transparent snapshot of the regulatory, clinical, and research evidence currently available for this procedure. Published evidence continues to evolve; long-term studies remain ongoing.
- FDA Regulatory Status— De Novo + 510(k) clearances Available
- Human Studies Published
- Peer-Reviewed Publications Published
- Long-Term Data (>5 years)— Follow-up ongoing Limited
- Ongoing Clinical Trials— Chile and Italy registries Active
Scientific References
Selected primary sources informing this page. External links open in a new tab; we do not control or endorse third-party content.
- FDAU.S. FDA — De Novo Classification DEN240013: MagDI System (Magnetic Duodeno-Ileostomy), De Novo marketing authorization granted July 2, 2024.
- FDAU.S. FDA — 510(k) Premarket Notification K242086: MagDI System (second generation), clearance granted October 24, 2024.
- Obesity SurgeryGagner M, et al. First-in-human experience of magnetic duodeno-ileostomy for the treatment of obesity and metabolic disease. Obesity Surgery.
- Surgical EndoscopyMulti-center early outcomes of sleeve gastrectomy combined with magnetic duodeno-ileostomy (Sleeve Plus MagDI). Surgical Endoscopy.
- ADAAmerican Diabetes Association — Standards of Care in Diabetes (current edition), Section on obesity and metabolic surgery.
- ClinicalTrials.govMagDI Chile — A study to evaluate the safety, feasibility, and initial efficacy of the MagDI System in adults with obesity with or without Type 2 Diabetes.
- ClinicalTrials.govMagDI Italy — A study to evaluate the safety, performance, and clinical outcomes of the MagDI System.
Frequently asked questions
Your next step starts here.
Our international care team typically responds within one business day. WhatsApp available 24/7 for urgent inquiries.
Choose Magnetic Precision. Metabolic Remission. Start today.
Limited slots for international patients. Same-week availability from San Diego.